Life sciences applied to technology
The FDA has granted accelerated approval to camizestrant plus a CDK4/6 inhibitor when an ESR1 resistance mutation emerges in blood ctDNA during first-line therapy, before imaging shows progression. SERENA-6 reported median PFS of 16.0 versus 9.2 months; overall survival remains immature.
A peer-reviewed rat-hippocampus experiment improves the detection limit from 107 to 68 pT/√Hz at 1 kHz, suppresses 50 Hz interference by about 98%, and records polarity-reversing magnetic spikes associated with action potentials. It is not yet a human implant or proof of isolated single-neuron TMR recording.
Mimrylo’s approval validates a new mechanism in polycythemia vera, but VERIFY still has to be read through its outcomes, adverse effects, and duration limits.
ACACIA-HCM improved both primary outcomes at 36 weeks, with a modest mean effect and a reversible ejection-fraction signal that requires careful clinical interpretation.
After loading, a molecular barrier changes wettability and releases a visible flow: 10 aM in 2 min for laboratory-prepared N RNA and 100 aM in 5 min for two viral fragments. The article reports complete agreement for the samples tested but contains an ambiguous internal RT-PCR metric; the ex vivo workflow adds 10 min of lysis.
By combining five assays and 4,804 experiments on 332 poorly characterized transcription factors and 61 controls, Codebook obtains motifs for 177 of the 332 candidates and expands the known human lexicon by at least 15%.